NephroGenex, Inc. (NRX) is no longer an active publicly traded company. The company filed for bankruptcy and was delisted from the NASDAQ stock exchange in 2017. Prior to its bankruptcy, NephroGenex was a clinical-stage biopharmaceutical company that focused on developing treatments for kidney diseases.
NephroGenex, Inc. (NRX) is no longer an active publicly traded company. The company filed for bankruptcy and was delisted from the NASDAQ stock exchange in 2017. Prior to its bankruptcy, NephroGenex was a clinical-stage biopharmaceutical company that focused on developing treatments for kidney diseases.